**HIV-1 Integrase Assay Kit**

**Version 3.0**  
**Catalog Number EZ-1700**

**INTRODUCTION**

HIV DNA is integrated into host DNA by a viral encoded integrase and this enzyme activity is a likely target site in the HIV life cycle to block viral infection.

The XpressBio HIV-1 Integrase Assay Kit is a non-radioactive assay used to quantitatively measure integrase activity, the effects of interacting proteins, anti-viral compounds, and other test articles on HIV-1 integrase activity. Streptavidin-coated 96-well plates are coated with a double-stranded HIV-1 LTR U5 donor substrate (DS) DNA containing an end-labeled biotin. Full-length recombinant HIV-1 integrase protein is loaded onto the DS DNA substrate. Integrase test articles are added to the enzyme reaction and then a different double-stranded target substrate (TS) DNA containing a 3'-end modification is added to the reaction mixture. The HIV-1 integrase cleaves the terminal two bases from the exposed 3'-end of the HIV-1 LTR DS DNA and then catalyzes a strand-transfer recombination reaction to integrate the DS DNA into the TS DNA. The products of the reaction are detected colorimetrically using an HRP-labeled antibody directed against the TS 3'-end modification. Sodium azide is included in the kit as a positive control compound that inhibits HIV-1 integrase catalytic activity.

**KIT CONTENTS**

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalogue</th>
<th>Per Kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reaction Buffer</td>
<td>EZ-1701</td>
<td>230 mL</td>
</tr>
<tr>
<td>Blocking Buffer</td>
<td>EZ-1702</td>
<td>30 mL</td>
</tr>
<tr>
<td>DS Oligo DNA 100X Solution</td>
<td>EZ-1703</td>
<td>120 μL</td>
</tr>
<tr>
<td>HIV-1 Integrase (2 μM)</td>
<td>EZ-1704</td>
<td>60 μL</td>
</tr>
<tr>
<td>Sodium Azide (20%)</td>
<td>EZ-1705</td>
<td>2 X 1 mL</td>
</tr>
<tr>
<td>TS Oligo DNA 100X Solution</td>
<td>EZ-1706</td>
<td>60 μL</td>
</tr>
<tr>
<td>HRP Antibody Solution</td>
<td>EZ-1707</td>
<td>12 mL</td>
</tr>
<tr>
<td>Dilution Plate</td>
<td>EZ-1708</td>
<td>1 plate</td>
</tr>
<tr>
<td>Streptavidin-coated 96-well Plate</td>
<td>EZ-1709</td>
<td>1 plate</td>
</tr>
<tr>
<td>Wash Buffer Concentrate 20X</td>
<td>82710</td>
<td>60 mL</td>
</tr>
<tr>
<td>TMB Peroxidase Substrate</td>
<td>XB-1006</td>
<td>12 mL</td>
</tr>
<tr>
<td>Stop Solution</td>
<td>XB-1007</td>
<td>12 mL</td>
</tr>
<tr>
<td>Instruction Manual</td>
<td>NA</td>
<td>1</td>
</tr>
</tbody>
</table>

**TECHNICAL ASSISTANCE**

Please refer any technical questions to info@xpressbio.com.

**SAFETY INFORMATION**

Sodium azide may react with lead and copper plumbing to form explosive azide compounds. When disposing of reagents, flush with copious quantities of water. The MSDS for this kit is available online at www.expressbiotech.com.

**STORAGE CONDITIONS**

The streptavidin-coated plate, reaction buffer, block buffer, sodium azide, HRP antibody, TMB, wash solution, and the stop solution should be placed at 2-8°C. The DS and TS DNAs, and the integrase enzyme should be stored at -20°C or cooler. The kit is stable for one year under these conditions.

Microwell strips of the streptavidin-coated plate that are not used after opening the foil pouch should be returned to the pouch along with the sachet of desiccant, closed with a pouch sealer or adhesive tape, and stored at 2-8°C until the expiration date on the label.

Reaction buffer (2 ml per reaction well) should be activated by the addition of β-mercaptoethanol (BME, 0.4 μl/1 ml) just prior to assay. BME-activated reaction buffer is stable for one week at 2-8°C. Reaction buffer may settle during storage, so the bottle should be warmed to 37°C and mixed before use.

**REAGENTS AND EQUIPMENT SUPPLIED BY THE USER**

- Pipettors and sterile tips
- Disposable gloves
- 14.5 M β-mercaptoethanol (BME)
- Paper towels
- Sterile distilled (deionized) water
- A 37°C incubator
- A 37°C water bath
- A 96-well plate reader capable of reading at 450 nm

**NOTES BEFORE STARTING**

**General Comments**

Carefully review the protocol before beginning, since small deviations may lead to discrepancies in the final results. All incubation steps should be performed within +/- 2 min of the indicated times.

Each lot of ExpressBio HIV Integrase Assay Kit has been extensively tested and the conditions under which the kit is shipped and stored have been shown empirically to not impact assay performance.

As with all other 96-well applications, there may be a slight difference in assay performance when the plate outer wells, and especially the plate corners are used. Consequently, the inner wells of the plate should be used preferentially in your experimental design whenever critical results are required.

**Wash Buffer Concentrate**

Wash buffer is provided as a 20X concentrate. Mix 50 mL of 20X wash buffer concentrate with 950 mL sterile distilled water to make a 1X wash buffer solution before use.
HIV INTEGRASE ASSAY KIT PROTOCOL

DS Coating and Blocking of SA Plate

1. Prewarm reagents

Place the reaction buffer and the blocking solution in a 37°C water bath for 10 min before starting the assay. Prewarm all the other components of the kit except the HIV-1 integrase enzyme by placing them at room temperature.

2. Coat with DS DNA

Remove any strip wells from the streptavidin-coated 96-well plate that will not be used and reseal them in the foil pouch containing desiccant. Dilute the required amount of DS DNA 100X solution 100-fold in reaction buffer (10 µL DS DNA 100X solution and 990 µL reaction buffer). Add 100 µL of 1X DS DNA solution per well and incubate for 30 min in a 37°C incubator. Return the reaction buffer to the 37°C water bath.

3. Blocking the plate

Aspirate the liquid from the plate wells and wash five times with 300 µL 1x wash buffer. Add 200 µL of blocking buffer per well and incubate for 30 min in a 37°C incubator.

If required, the plate may now be placed at 2-8°C overnight and later placed in a 37°C incubator for 20 min before continuing with the protocol, however the kit performs slightly better if the entire protocol is performed in one day.

Integrate Reaction

4. Load the integrase onto DS DNA

Thaw the HIV-1 integrase on wet ice or at 2-8°C (~5 min) before it is needed and centrifuge the tube briefly (ex. 10,000 RPM X 5 sec) before use. Dilute the enzyme 1:300 into reaction buffer (2 µL HIV-1 integrase and 598 µL reaction buffer). Aspirate the liquid from the plate wells and wash three times with 200 µL reaction buffer. Add 100 µL of reaction buffer (negative control) or integrase enzyme solution (positive control) per well and incubate for 30 min in a 37°C incubator. Include reaction buffer only replicates (without integrase) as a no enzyme negative control. Return the reaction buffer to the 37°C water bath.

5. Add Inhibitors or Test Articles

Prepare test articles by diluting to 2X final desired test concentration in reaction buffer. For example, prepare a 20 µM or 20 µg/mL solution and serially dilute in reaction buffer when a 10 µM or 10 µg/mL high-test concentration is desired for the assay. Azide solution diluted to 0.30% (2X concentration or 0.15% final 1X concentration) inhibits approximately 50% of the integrase activity. Include 50 µL reaction buffer negative and positive control replicates (no test article) in each experiment. Test articles may contain up to 10% dimethyl sulfoxide (DMSO), since the integrase reaction is only marginally affected by the presence of up to 5% DMSO in the final reaction.

Aspirate the liquid from the plate wells and wash them three times with 200 µL reaction buffer. Add 50 µL per well of each test article in reaction buffer (reaction buffer alone for positive and negative controls) and incubate for 5 min at room temperature.

6. Add TS DNA

Dilute the required amount of TS DNA 100X solution 100-fold in reaction buffer (10 µL TS DNA 100X solution and 990 µL reaction buffer per mL). Add 50 µL of the 1X TS DNA solution per well directly to the 50 µL buffer/test articles already present in the wells. Mix the reactions by tapping the plate gently against a stationary hand 3-5 times. Incubate for 30 min at 37°C.
Detection of Reaction Products

7. Add HRP Antibody

Aspirate the liquid from the plate wells and wash five times with 300 µL wash solution. Add 100 µL HRP antibody solution per well and incubate for 30 min at 37°C.

8. Add TMB Peroxidase Substrate

Aspirate the liquid from the plate wells and wash five times with 300 µL wash solution. Add 100 µL TMB peroxidase substrate solution per well and incubate for 10 minutes at room temperature.

9. Add TMB Stop Solution

Add 100 µL TMB stop solution directly to the wells containing the TMB substrate. Burst any large bubbles by using a pipette tip. Read the absorbance of the wells for a minimum of 0.1 sec using a plate reader set at 450 nm. Plates should be read within 10 min of adding TMB stop solution.

If the OD 450 nM absorbance is above the range of the plate reader, the reactions can be dilute in order to realize a more accurate reading or end point. Add 100 µL of the assay reaction wells to 100 µL of dH2O into the dilution plate/strip or well (EZ-1709 provided, do not use the SA-coated plate/strips) and read the absorbance at 450 nM. The absorbance values from the diluted samples should be multiplied by 2.

DATA ANALYSIS AND ASSAY PERFORMANCE

Experimental data are analyzed as described below; typically, duplicate or triplicate determinations are obtained for each control/sample/drug/test-article in each experiment.

Determine the mean blank absorbance (reaction buffer negative control) in the assay from the no integrase/no test article control (usually less than 0.25 OD units) and subtract this background absorbance from the other readings.

Calculate the mean +/- standard deviation (SD) and CV (SD/mean X 100%) for the background corrected absorbance of integrase alone (positive control) and test articles replicate wells.

Convert the data to percent control activity by dividing the mean absorbance of test articles by that of the integrase alone control and multiplying by 100%. The mean absorbance of the test articles divided by the mean integrase control activity multiplied by the associated CV provides the percent adjusted standard deviation. The CV = %SD for the 100% integrase alone control.

Typical assay results for buffer/no integrase, integrase alone/no azide, and integrase plus azide (each point run in triplicate) are tabulated below for the inhibition of the HIV-1 integrase when treated with azide:

A graph illustrating the dosage-dependent inhibitory effect of azide on the catalytic activity of the HIV-1 integrase is shown below.

![Graph illustrating the dosage-dependent inhibitory effect of azide on the catalytic activity of the HIV-1 integrase.](image)

The inhibitory concentration of azide that reduces integrase activity by 50% (IC50) may be interpolated from the curve manually or using more sophisticated programming. In this example, azide showed an IC50 of 0.15% and an IC90 of 0.57%.

A summary of the absorbance values observed for background-corrected integrase-alone (integrase) and for the IC50 and IC90 values for sodium azide observed in three independently-performed experiments are shown below.

<table>
<thead>
<tr>
<th>Expt</th>
<th>Integrase Alone</th>
<th>IC50 (% NaN3)</th>
<th>IC90 (%NaN3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.9 +/- 0.08</td>
<td>0.152</td>
<td>0.568</td>
</tr>
<tr>
<td>2</td>
<td>2.8 +/- 0.16</td>
<td>0.143</td>
<td>0.537</td>
</tr>
<tr>
<td>3</td>
<td>2.6 +/- 0.05</td>
<td>0.124</td>
<td>0.613</td>
</tr>
<tr>
<td>All</td>
<td>2.77 +/- 0.12</td>
<td>0.140 +/- 0.012</td>
<td>0.573 +/- 0.031</td>
</tr>
</tbody>
</table>

*Mean +/- SD background-corrected absorbance of six integrase alone control wells.

Note: The absorbance values generated by integrase alone may vary between experiments, but the IC50 and IC90 values are reproducible with CVs = 8.5% and 5.4%, respectively.
The data from a typical experiment with the HIV-1 integrase inhibitor Elvitegravir (EVG) are tabulated below:

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Mean OD (Corrected)</th>
<th>Std. Deviation (Corrected)</th>
<th>% CV</th>
<th>% Control Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reaction Buffer</td>
<td>0.000</td>
<td>0.007</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Integrase Alone</td>
<td>4.37</td>
<td>0.133</td>
<td>3.0%</td>
<td>100%</td>
</tr>
<tr>
<td>3.0 µM EVG</td>
<td>0.225</td>
<td>0.019</td>
<td>8.4%</td>
<td>5.1%</td>
</tr>
<tr>
<td>1.0 µM EVG</td>
<td>0.426</td>
<td>0.009</td>
<td>2.1%</td>
<td>9.7%</td>
</tr>
<tr>
<td>0.5 µM EVG</td>
<td>0.692</td>
<td>0.093</td>
<td>13.5%</td>
<td>15.8%</td>
</tr>
<tr>
<td>0.25 µM EVG</td>
<td>1.020</td>
<td>0.021</td>
<td>2.1%</td>
<td>23.3%</td>
</tr>
<tr>
<td>0.10 µM EVG</td>
<td>1.80</td>
<td>0.225</td>
<td>12.5%</td>
<td>41.0%</td>
</tr>
<tr>
<td>0.05 µM EVG</td>
<td>1.90</td>
<td>0.277</td>
<td>14.6%</td>
<td>43.4%</td>
</tr>
<tr>
<td>0.01 µM EVG</td>
<td>3.49</td>
<td>0.316</td>
<td>9.1%</td>
<td>79.9%</td>
</tr>
<tr>
<td>0.005 µM EVG</td>
<td>3.78</td>
<td>0.397</td>
<td>10.5%</td>
<td>86.4%</td>
</tr>
</tbody>
</table>

A graph illustrating the dosage-dependent inhibitory effect of Elvitegravir and Raltegravir on the catalytic activity of HIV-1 integrase is shown below.

The inhibitory concentration of Elvitegravir and Raltegravir that reduces integrase activity by 50% (IC₅₀) and 90% (IC₉₀) may be interpolated from the data and the curve. In this experiment, Elvitegravir showed an IC₅₀ of 40 nM and an IC₉₀ of 975 nM, while Raltegravir showed an IC₅₀ of 175 nM and an IC₉₀ of 2.88 µM.

**TROUBLESHOOTING GUIDE**

<table>
<thead>
<tr>
<th>Problem</th>
<th>Suggestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrase alone signal &gt;3.0</td>
<td>Dilute stopped reaction 1:1 in dH2O into a blank strip or well (do not use SA-coated plate). Dilute integrase enzyme at 1:350 in reaction buffer, see step 4 above.</td>
</tr>
<tr>
<td>Integrase alone signal &lt;0.5</td>
<td>Spin down integrase before use. Dilute integrase enzyme 1:250 in step 4 above. Increase the TMB incubation time to 20-30 min.</td>
</tr>
<tr>
<td>Wells are stained blue</td>
<td>Add stop reagent before reading plates or read plate at 405 nM instead of 450 nM.</td>
</tr>
<tr>
<td>Background is high &gt;0.35</td>
<td>Replace reaction buffer. Use reaction buffer within one week of adding BME. Swirl/mix the reaction buffer bottle before use. Review plate washing steps above.</td>
</tr>
</tbody>
</table>

**EXPERIENCED USERS PROTOCOL**

1. Prewarm reagents, 100 µL DS oligo, 30 min at 37°C.
2. 5 X 300 µL wash buffer, 200 µL block, 30 min at 37°C.
3. 3 X 200 µL reaction buffer wash, 100 µL of 1:300 dilution of integrase in reaction buffer, 30 min at 37°C.
4. 3 X 200 µL reaction buffer wash, 50 µL reaction buffer or test article in reaction buffer, 5 min at room temperature.
5. 50 µL of TS oligo, 30 min at 37°C.
6. 5 X 300 µL wash buffer, 100 µL HRP antibody, 30 min at 37°C.
7. 5 X 300 µL wash buffer, 100 µL/well of TMB substrate, 10 min at room temperature.
8. 100 µL TMB stop solution, read OD at 450 nM.

**CONTRACT RESEARCH**

Need a hand with your research? Would you like independent confirmation of your results? Why not let us perform the HIV-1 integrase assay for you? Contact us for more information.

**CONTACT INFORMATION**

Express Biotech International
503 Gateway Drive West
Thurmont, MD 21788 USA
Toll free: 888-562-8914
info@XpressBio.com
www.XpressBio.com
Tel: 301-228-2444
Fax: 301-560-6570